
Dec 16 (Reuters) - U.S. Health Secretary Robert F. Kennedy Jr. on Tuesday added two rare genetic disorders, Duchenne Muscular Dystrophy and Metachromatic Leukodystrophy, to the federal newborn screening list to enable early treatment, the Department of Health and Human Services said.
The decision updates the Recommended Uniform Screening Panel (RUSP), which guides state-level newborn screening programs, following a scientific review and public comment process.
Early detection of Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) will allow children to receive FDA-approved therapies at the most effective time, helping slow disease progression and preserve quality of life, the HHS said.
DMD, a rare genetic disorder, causes muscle degeneration, while MLD affects the brain and nervous system, which leads to loss of motor and cognitive function and early death.
Most children with DMD or MLD are diagnosed at age four or five, when significant muscle loss or neurological decline has already occurred, the HHS said.
The agency said that screening at birth could reduce years-long diagnostic delays, repeated specialist visits, and the financial and emotional strain often associated with rare diseases.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
74 suicide warnings and 243 mentions of hanging: What ChatGPT said to a suicidal teen - 2
Horror and fear in West Bank as Israel approves hanging Palestinians convicted of murdering Israelis - 3
New movies to watch this weekend: See 'They Will Kill You' in theaters, rent 'Send Help,' stream 'Pretty Lethal' on Prime Video - 4
Gaza amputees struggle to rebuild lives as the enclave faces shortages of prosthetic limbs - 5
Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest
Eco-Accommodating Kitchen Machines: 4 Picks for a Manageable Home
America's Confided in Cooler in 2024
A 3-limbed Kemp's ridley sea turtle is now being tracked at sea by satellite
Iranian missile hit on Ne'ot Hovav factory leads to fear of chemical leakage
Compassion and Association: Building Significant Connections
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
Figure out how to Consolidate All encompassing Practices with a Degree in Brain research
The most effective method to Plan an Incineration Administration: A Bit by bit Guide.
Former GLP-1 users regain lost weight after about 18 months, study says













